When a biopharmaceutical company rises to the top, and is globally recognized as one of the best companies in its industry, it’s already achieved perfection. But Samsung Biologics views the fact that they are one of the best as a challenge. The CDMO is constantly trying to change how the world sees biopharmaceutical companies through its progress, expansion, and quality services.
While the rest of the world is slowly trying to recover from the effects of a global pandemic on the economy, Samsung Biologics has hit the ground running. The company managed to expand during a time when most businesses were shutting down. They found new partners, new horizons, and made plans to build even more facilities around the globe.
What are the key features that make a biopharmaceutical company stand out?
- A commitment to its mission
- Consistent effort to continue improving services
- Demonstrable success in the business world.
In the past year, Samsung Biologics has achieved all three of these goals. Yet they aren’t satisfied with simply stopping there. The company plans to do more, supply more, make even more partnerships and offer its services to more medical researchers and pharmaceutical companies.
Biopharmaceutical companies play a key role in the restoration of the world and the global market after the destructive COVID-19 pandemic. It is only thanks to their efforts that vaccines can be distributed to more than seven billion people. Unfortunately, even though more than 900 million people have already been vaccinated as of June 2021, that number is still only 12 percent of the global population. Many countries have no members of their population that have been vaccinated. They are still suffocating from the effects of the COVID-19 pandemic. Companies like Samsung Biologics play a crucial role in releasing these nations from the burden of a deadly virus.
In the past six months, Samsung Biologics has made several partnerships with leading pharmaceutical companies to assist them in their goals for helping the world heal from COVID-19, and other diseases as well.
One partnership included Moderna, one of the world’s top producers of a COVID-19 vaccine that has been proven to be safe, effective, and accessible. Samsung Biologics agreed to help produce hundreds of millions of COVID-19 vaccines for the company in order to get them distributed across the globe, especially in places where vaccines have not been available previously.
“This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine,” said John Rim, CEO of Samsung Biologics. “Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedules to make mRNA-1273 available for commercial distribution in the early second half of 2021.”
“We are pleased to partner with Samsung Biologics for this fill and finish manufacturing, which will help us continue to scale up our manufacturing capacity outside of the U.S.,” said Juan Andres, Moderna’s Chief Technical Operations and Quality Officer. “We and our manufacturing partners remain committed to defeating the COVID-19 pandemic.”
Another strategic partnership the biopharmaceutical company made was with KAHR Medical Ltd., a cancer immunotherapy company. Despite the global focus on COVID-19, other diseases and conditions did not stop spreading or harming human individuals. Medical researchers needed to spend just as much time on ways to cure conditions like cancer.
“We are proud to announce our partnership with KAHR Medical for the production of their novel drug candidate,” said John Rim, CEO of Samsung Biologics. “We will leverage our fully integrated, scalable, and high-quality development services and experienced teams to enable a faster transition from gene to IND in order to ensure KAHR’s success in bringing cutting edge immuno-recruitment cancer drugs to patients in need.”
Samsung Biologics supplied end-to-end cell line development and clinical drug substance and drug product manufacturing services as well as IND filling support for KAHR’s drug candidate DSP502, a TIGITxPD1 fusion protein.
Certifications for Quality
Samsung Biologics has also strived for demonstrable quality when it comes to its services and production capacity. In June 2021, the biopharmaceutical company announced that it had received four global ISO certifications: ISO22301 (Business Continuity Management), ISO50001 (Energy Management), ISO45001 (Occupational Health and Safety Management), and ISO14001 (Effective Environmental Management) from the British Standards Institution (BSI).
These certifications proved that the company was capable of operating in a high-stress environment, leading the world in terms of production and manufacturing, and meeting environmental standards, a crucial role for a business engaged in making the world a better place to live. Samsung Biologics does not view itself in light of simple CDMO standards, but instead embraces a holistic view where employees are safe and happy, and no environmental damage is done.
“We are extremely proud to obtain four global ISO certifications during a time where a high degree sustainable management system is vital, especially in light of COVID-19, to stably operate and supply crucial biomedicines for patients,” John Rim, CEO of Samsung Biologics, said of the four certifications. “Samsung Biologics is a leading CDMO committed to taking responsibility and consideration of ESG factors across all of our business areas, and we will continue to enhance our capabilities to meet the evolving needs of clients whilst ensuring the safety and security of not only our people but also of the environment to ultimately create a better future for humanity.”